Finally, galectin-3 being a cancer drug target, the noncanonical binding regions of galectin-3, as reported in the current work, can be used to develop possible lead molecules that can target the sites, which in turn can reduce the binding affinity of galectin-3 to polysaccharides, since it has been proposed that binding on one side attenuates the binding affinity of the other side (22). Here, LGALS3 is linked to cancer.